Limits...
Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: Recently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER+ breast cancer cells. In this paper, we characterize allografts of ER+ E0771 mouse breast tumor cells in immunocompetent C57BL/6 mice, and also analyze the effect of meroxest on the prognosis of the disease.

Material and methods: Twenty female C57BL/6 mice were injected with 106 E0771 cells. Once the tumors reached the appropriate size, the mice were divided into two groups, one control and another treated orally with 15 mg/kg of meroxest. After 20 days, tumor samples were taken for histopathological study and for determination of the expression of the prognostic markers Ki67 and vascular endothelial growth factor (VEGF) by immunofluorescence.

Results: In sections stained with hematoxylin-eosin, we observed that tumors have a well-defined capsule enclosing E0771 tumor cells. The central area of tumors contains necrotic regions with leukocyte infiltration. Meroxest treatment significantly reduces tumor size (68%, p < 0.05), induces changes in its structure, decreases the degree of leukocyte infiltration, and significantly reduces the expression of Ki67 (33%, p < 0.05) and VEGF (82%, p < 0.05).

Conclusions: Meroxest improves the prognosis of mice since it reduces leukocyte infiltration, and decreases the expression of Ki67 and VEGF markers. Consequently, the merosesquiterpene could become a useful antiangiogenic drug in the treatment of breast cancer. These results encourage us to deepen the study of meroxest, in order to find more evidence that supports the convenience of its evaluation in a clinical study or trial.

No MeSH data available.


Related in: MedlinePlus

Allografts of E0771 cells in C57BL/6 mice. A – Mouse bearing a tumor (arrow). B – Samples of tumors: whole tumor from control (left) and from 15 mg/kg meroxest-treated animal (right) (B1). The mean volume of control tumors was 12.14 × 103 mm3, whereas that of tumors treated with meroxest was 3.89 × 103 mm3. Fragments from control tumors (B2) and from 15 mg/kg meroxest-treated tumors (B3). Arrows in B3 indicate areas with marked modifications in the structure of meroxest-treated tumors as compared to controls. Bars: 24 mm (B1) and 15 mm (B2 and B3)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016567&req=5

Figure 0002: Allografts of E0771 cells in C57BL/6 mice. A – Mouse bearing a tumor (arrow). B – Samples of tumors: whole tumor from control (left) and from 15 mg/kg meroxest-treated animal (right) (B1). The mean volume of control tumors was 12.14 × 103 mm3, whereas that of tumors treated with meroxest was 3.89 × 103 mm3. Fragments from control tumors (B2) and from 15 mg/kg meroxest-treated tumors (B3). Arrows in B3 indicate areas with marked modifications in the structure of meroxest-treated tumors as compared to controls. Bars: 24 mm (B1) and 15 mm (B2 and B3)

Mentions: We found that the rate of tumor formation using allografts of E0771 cells in immunocompetent C57BL/6 mice was very high, over 95% of cases. In Figure 2A, a mouse bearing a tumor can be observed, and panel 2B shows photographs of tumors isolated from the sacrificed animals. The mean volume of control tumors was 12.14 × 103 mm3, whereas that of tumors treated with meroxest was 3.89 × 103 mm3. Macroscopically, we found that meroxest significantly reduces tumor size (Figure 2B1), and also that it induces changes in tumor structure, as compared to controls (Figure 2B2 vs. 2B3). We found important differences in the texture of tumors, since controls showed a consistency similar to liver, while tumors of animals treated with meroxest presented a more compact and robust consistency, similar to cartilage tissue (Figure 2B3).


Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells
Allografts of E0771 cells in C57BL/6 mice. A – Mouse bearing a tumor (arrow). B – Samples of tumors: whole tumor from control (left) and from 15 mg/kg meroxest-treated animal (right) (B1). The mean volume of control tumors was 12.14 × 103 mm3, whereas that of tumors treated with meroxest was 3.89 × 103 mm3. Fragments from control tumors (B2) and from 15 mg/kg meroxest-treated tumors (B3). Arrows in B3 indicate areas with marked modifications in the structure of meroxest-treated tumors as compared to controls. Bars: 24 mm (B1) and 15 mm (B2 and B3)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016567&req=5

Figure 0002: Allografts of E0771 cells in C57BL/6 mice. A – Mouse bearing a tumor (arrow). B – Samples of tumors: whole tumor from control (left) and from 15 mg/kg meroxest-treated animal (right) (B1). The mean volume of control tumors was 12.14 × 103 mm3, whereas that of tumors treated with meroxest was 3.89 × 103 mm3. Fragments from control tumors (B2) and from 15 mg/kg meroxest-treated tumors (B3). Arrows in B3 indicate areas with marked modifications in the structure of meroxest-treated tumors as compared to controls. Bars: 24 mm (B1) and 15 mm (B2 and B3)
Mentions: We found that the rate of tumor formation using allografts of E0771 cells in immunocompetent C57BL/6 mice was very high, over 95% of cases. In Figure 2A, a mouse bearing a tumor can be observed, and panel 2B shows photographs of tumors isolated from the sacrificed animals. The mean volume of control tumors was 12.14 × 103 mm3, whereas that of tumors treated with meroxest was 3.89 × 103 mm3. Macroscopically, we found that meroxest significantly reduces tumor size (Figure 2B1), and also that it induces changes in tumor structure, as compared to controls (Figure 2B2 vs. 2B3). We found important differences in the texture of tumors, since controls showed a consistency similar to liver, while tumors of animals treated with meroxest presented a more compact and robust consistency, similar to cartilage tissue (Figure 2B3).

View Article: PubMed Central - PubMed

ABSTRACT

Introduction: Recently, we have reported the antitumor properties of a new family of synthetic merosesquiterpenes, among which meroxest is highlighted, since it has high activity and specificity for ER+ breast cancer cells. In this paper, we characterize allografts of ER+ E0771 mouse breast tumor cells in immunocompetent C57BL/6 mice, and also analyze the effect of meroxest on the prognosis of the disease.

Material and methods: Twenty female C57BL/6 mice were injected with 106 E0771 cells. Once the tumors reached the appropriate size, the mice were divided into two groups, one control and another treated orally with 15 mg/kg of meroxest. After 20 days, tumor samples were taken for histopathological study and for determination of the expression of the prognostic markers Ki67 and vascular endothelial growth factor (VEGF) by immunofluorescence.

Results: In sections stained with hematoxylin-eosin, we observed that tumors have a well-defined capsule enclosing E0771 tumor cells. The central area of tumors contains necrotic regions with leukocyte infiltration. Meroxest treatment significantly reduces tumor size (68%, p < 0.05), induces changes in its structure, decreases the degree of leukocyte infiltration, and significantly reduces the expression of Ki67 (33%, p < 0.05) and VEGF (82%, p < 0.05).

Conclusions: Meroxest improves the prognosis of mice since it reduces leukocyte infiltration, and decreases the expression of Ki67 and VEGF markers. Consequently, the merosesquiterpene could become a useful antiangiogenic drug in the treatment of breast cancer. These results encourage us to deepen the study of meroxest, in order to find more evidence that supports the convenience of its evaluation in a clinical study or trial.

No MeSH data available.


Related in: MedlinePlus